Mark Foley, Revance Therapeutics CEO

Longer-last­ing Botox com­peti­tor nabs FDA ap­proval — can it com­pete with Ab­b­Vie's $2B cash cow?

Re­vance Ther­a­peu­tics an­nounced Thurs­day that its first FDA ap­proval has fi­nal­ly ar­rived for its Botox com­peti­tor, known as Daxxi­fy, af­ter ini­tial­ly sub­mit­ting its orig­i­nal BLA way back in Jan­u­ary 2020.

The bot­u­linum tox­in prod­ucts will com­pete to tem­porar­i­ly im­prove mod­er­ate to se­vere frown lines, and for what Re­vance es­ti­mates is a $3.2 bil­lion and grow­ing mar­ket.

Re­vance is look­ing to cor­ner a slice of that mar­ket with its longer-last­ing, po­ten­tial­ly twice-year­ly in­jec­tion, where­as those us­ing Botox may have to re­turn for more in­jec­tions every three to four months. Wall Street biotech an­a­lysts pre­vi­ous­ly in­di­cat­ed that this dif­fer­ence may be key for Re­vance in do­ing bet­ter than oth­er pre­vi­ous­ly launched Botox knock-offs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.